Viridian Therapeutics, Inc.\DE - Common Stock, par value $0.01 per share (VRDN)

CUSIP: 92790C104

Q2 2026 13F Holders as of 30 Jun 2026

Holder snapshot 7 signals
Share change
+22,915,781
Put/Call ratio
22%
SEC-reported price per share
$18.37
Number of holders
213
Value change
+$413,360,251
Number of buys
139
Open additional details 1 more signal available
Number of sells
105
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
113,750,140

Security key

92790C104

Report period

Q2 2026

Institutions

213

Top holders

10

Ownership snapshot

Top reported holders of VRDN - Viridian Therapeutics, Inc.\DE - Common Stock, par value $0.01 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Fairmount Funds Managemen...
Disclosed value leader
FMR LLC
Comparable rows
15/15
Latest evidence
30 Jun 2026
13D/G 3/4/5 13F Lead comparable stake: 14% 13D/G row: Fairmount Funds Management LLC Showing 1-6 of 15 holder rows.

Quick read

Fairmount Funds Management LLC leads the comparable SEC ownership view at 14%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Fairmount Funds Management LLC's linked filing trail.
Comparable ownership Top 5
Fairmount Funds Management LLC 14%
Bellevue Group AG 6.6%
Paradigm Biocapital Advisors LP 6.1%
Kynam Capital Management, LP 5.7%
STATE STREET CORP 5.5%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Fairmount Funds Management LLC
13D/G 3/4/5 13F
Director, 10%+ Owner · Company
14%
$239,105,020
17,201,800 shares
+$16,352,933 11 May 2026
Bellevue Group AG
13F 13D/G
Company
6.6%
from 13D/G
$131,563,376
6,726,144 shares
31 Mar 2026
Paradigm Biocapital Advisors LP
13D/G 13F
Company
6.1%
$132,727,575
6,723,788 shares
+$21,516,600 30 Jun 2026
Kynam Capital Management, LP
13F 13D/G
Company
5.7%
from 13D/G
$45,802,713
2,341,652 shares
31 Mar 2026
STATE STREET CORP
13D/G 13F
STATE STREET CORPORATION · Company
5.5%
$120,907,026
6,124,976 shares
$0 30 Jun 2026
PRICE T ROWE ASSOCIATES INC /MD/
13D/G 13F
T. Rowe Price Associates, Inc. · Company
5.2%
$113,473,929
5,748,426 shares
$0 30 Jun 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
213
Shares
136,040,611
Rows available
213
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2026 vs Q1 2026 Across Filers

Q1 2026 holders
223
Q2 2026 holders
213
Holder diff
-10
Investor Q1 2026 Shares Q2 2026 Shares Share Diff Share Chg % Q1 2026 value Q2 2026 value Value change Value Chg %
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .